NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Employees

Sector

Biotechnology & Medical Research

Calendar

06-23 - Significant Split/Dividend

More about the company

Income Statement and Estimates

More financial data

End-of-day quote Deutsche Boerse AG Other stock markets 11:06:03 15/11/2023 +04			5-day change	1st Jan Change
0.000500 ^EUR	-.--%		-.--%	-

02-11	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
11-21	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI

Market Cap	4.15K 4.81K 3.82K 3.58K 6.72K 455K 6.79K 45.11K 17.62K 223K 18.05K 17.67K 770K	P/E Ratio 2023 *	-	P/E Ratio 2024	-
Enterprise Value	-201K -233K -185K -173K -326K -22.03M -329K -2.19M -854K -10.79M -875K -856K -37.34M	EV / Sales 2023	-	EV / Sales 2024	-0.12x
Free-Float	1.27%	Yield 2023 *	-	Yield 2024	-

02-11	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
11-21	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
21/10/25	Neovacs S.A. announced that it expects to receive ?0.25 million in funding	CI
12/08/25	Neovacs S.A. announced that it has received ?0.25 million in funding from European High Growth Opportunities Manco S.A.	CI
30/04/25	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
30/04/25	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/03/25	Neovacs S.A. announced a financing transaction	CI
04/02/25	Neovacs: consideration of delisting, share price surges
04/11/24	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
01/11/24	Tech's Tangled Path with Microsoft
17/06/24	Neovacs: collaboration agreement with CNRS
10/06/24	Neovacs: presents results from vaccine candidates
04/06/24	Néovavs: raises 200,000 euros through the issue of OCEANE-BSA bonds

04:26pm	Financements dilutifs et fonds vautours : le législateur s'en mêle enfin
05-22	Bourse : Richemont brille, Estée Lauder renonce à Puig, Kioxia grossit
05-22	L'IA reprend le leadership
05-04	Bourse : GameStop veut racheter Ebay, game over pour Spirit, Engie accélère dans l'éolien
05-04	Coup de théâtre ou coup d'épée dans l'eau ?

NEOVACS SA Stock Deutsche Boerse AG

Stocks

0LW

FR001400HDX0

Biotechnology & Medical Research

Valuation: NEOVACS SA

Latest news : NEOVACS SA

News in other languages: NEOVACS SA

Quotes and Performance

Course Extremes

Managers and Directors: NEOVACS SA

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	01/10/2020
Laurent Reber CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jean-Jacques Bertrand CHM	Chairman	87	28/05/2003
Baudouin Hallo BRD	Director/Board Member	-	01/05/2020
Hugo Brugière CHM	Chairman	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEOVACS SA	-.--%	-.--%	-	-	368K
LONZA GROUP AG	+0.96%	+1.16%	-12.70%	-12.33%	43.03B
REVOLUTION MEDICINES, INC.	+3.83%	+7.60%	+301.76%	+535.56%	32.71B
IQVIA HOLDINGS INC.	-2.09%	-3.66%	+11.13%	-18.36%	30.29B
BEONE MEDICINES AG	+0.67%	-1.81%	+0.56%	+32.27%	29.4B
CELLTRION, INC.	+1.16%	+2.10%	+14.27%	+22.05%	25.08B
ASCENDIS PHARMA A/S	+2.32%	+8.47%	-	-	13.54B
MEDPACE HOLDINGS, INC.	-0.23%	+1.69%	+54.70%	+111.06%	13.35B
EUROFINS SCIENTIFIC SE	-1.09%	-2.31%	+3.49%	+5.00%	12.97B
IONIS PHARMACEUTICALS, INC.	+0.33%	+0.12%	+108.94%	+76.61%	12.11B
Average	+0.59%	+0.83%	+60.27%	+93.98%	23.61B
Weighted average by Cap.	+0.71%	+0.82%	+60.98%	+102.60%

	2023	2024
Net sales	533K 619K 491K 461K 865K 58.49M 874K 5.8M 2.27M 28.64M 2.32M 2.27M 99.11M	434K 503K 399K 375K 704K 47.58M 711K 4.72M 1.84M 23.3M 1.89M 1.85M 80.63M
Net income	-8.74M -10.14M -8.05M -7.55M -14.18M -959M -14.32M -95.13M -37.16M -469M -38.07M -37.26M -1.62B	-32.91M -38.19M -30.29M -28.42M -53.38M -3.61B -53.91M -358M -140M -1.77B -143M -140M -6.12B
Net Debt	-237K -274K -218K -204K -384K -25.93M -387K -2.57M -1.01M -12.7M -1.03M -1.01M -43.94M	-205K -238K -189K -177K -333K -22.49M -336K -2.23M -872K -11.01M -893K -874K -38.11M

1 week	0		5
1 month	0		10